Highest-materiality recent filing
Bolt Biotherapeutics reports 2026 annual meeting voting results
At June 10, 2026 annual meeting, 877,358 of 1,921,567 outstanding shares represented.
Bolt Biotherapeutics reports Q1 2026 results; cash $23.9M, BDC-4182 data expected Q3 2026
Initial clinical data from BDC-4182 Phase 1/2 study for gastric/gastroesophageal cancer anticipated in Q3 2026.
Bolt Biotherapeutics reports FY2025 loss from ops $36.1M; cash $31.8M into 2027
Collaboration revenue $7.7M for FY2025, flat YoY; Q4 2025 revenue $2.5M vs $0 in Q4 2024.
Bolt Biotherapeutics Q3 2025: operating loss $7.7M, cash $38.8M; BDC-4182 data expected 3Q26
Collaboration revenue $2.2M (vs $1.1M Q3 2024); R&D expenses $6.5M (down 53% YoY).
Bolt Biotherapeutics cuts workforce 50% and delays BDC-4182 data to Q3 2026
Workforce reduced by ~50% (approx. 20 employees); pre-tax charges $1.5-2.0M in Q4 2025.
Bolt Biotherapeutics Q2 2025 loss from ops $9.2M; cash $48.5M; BDC-4182 Phase 1 ongoing
Collaboration revenue $1.8M (Q2 2024: $1.3M); R&D expenses down to $7.5M from $15.4M.
Bolt Biotherapeutics effects 1-for-20 reverse stock split
Reverse stock split at 1-for-20 ratio effective June 6, 2025.
Bolt Biotherapeutics announces 1-for-20 reverse stock split effective June 6, 2025
Reverse stock split ratio 1:20 approved by board on May 27, 2025.
Bolt Biotherapeutics stockholders approve reverse stock split amendment at 2025 annual meeting
Reverse stock split amendment approved: 20,983,236 votes for, 3,224,611 against (86.9% of votes cast).
Bolt Biotherapeutics Q1 2025: operating loss $12.1M; cash $58M; BDC-4182 Phase 1 open
Collaboration revenue $1.2M (down from $5.3M in Q1 2024) due to completion of Innovent agreement.
Bolt Biotherapeutics amends bylaws to reduce stockholder quorum to one-third of shares
Board amended bylaws on April 15, 2025, effective immediately.
Bolt Biotherapeutics Q4 2024 loss from ops $16.9M; cash $70.2M; BDC-4182 starts trial Q2 2025
Q4 2024 loss from operations $16.9M vs $19.8M in Q4 2023; full-year loss $73.0M vs $76.2M.
Transfer approved Jan 2, 2025; effective at market open Jan 6, 2025.
Director Mahendra Shah resigns from Bolt Biotherapeutics board; Dupont added to two committees
Dr. Mahendra Shah notified his resignation on Dec 19, effective Dec 31, 2024, for personal reasons.
Bolt Biotherapeutics Q3 2024: cash $84.4M; BDC-3042 advances to 10 mg/kg cohort
Cash $84.4M as of Sept 30, 2024; expected to fund operations through mid-2026.
Bolt Biotherapeutics appoints Dr. Jakob Dupont to Board; two directors resign
James Healy, M.D., Ph.D., resigned from Board effective Sept 3, 2024; no disagreement with company.
Bolt Biotherapeutics Q2 2024 loss from operations $22.6M; cash $97.5M, BDC-3042 advances to Cohort 6
Loss from operations of $22.6M for Q2 2024 vs $19.8M in Q2 2023; restructuring charges of $3.6M.
Bolt Biotherapeutics receives Nasdaq bid price deficiency notice; 180 days to comply
Avg closing price of common stock fell below $1.00 over prior 30 trading days as of July 1, 2024.
Bolt Biotherapeutics annual meeting elects directors and ratifies auditor
Director Kathleen LaPorte elected with 12,706,287 votes for, 3,990,176 withheld, 9,231,722 broker non-votes.
Bolt Biotherapeutics restructures, cuts 50% workforce, CEO replaced; Q1 loss $17.1M
Q1 2024: loss from ops $17.1M; collaboration revenue $5.3M; cash $112.8M.
Bolt Biotherapeutics reports Q4/FY2023 results; cash $128.6M funds through late 2025
Cash, cash equivalents, and marketable securities at $128.6M as of Dec 31, 2023; expected to fund through late 2025.
Bolt Biotherapeutics Q3 2023: cash $141.4M, BDC-1001 29% ORR, BDC-3042 dosed
Cash, cash equivalents and marketable securities of $141.4M as of Sept 30, 2023; expected to fund operations through 2025.
Bolt Biotherapeutics Q2 2023 cash $157.1M, initiates BDC-1001 Phase 2, gets IND for BDC-3042
Cash, equivalents and marketable securities $157.1M as of June 30, 2023; runway expected through 2025.
Bolt Biotherapeutics annual meeting elects three directors, ratifies PwC as auditor
Randall C. Schatzman, Ph.D. elected with 18,339,155 votes for, 49,830 withheld.
Bolt Biotherapeutics Q1 2023 net loss $18.4M; cash $171M; BDC-1001 Phase 2 plans
Net loss from operations $18.4M vs $23.9M in Q1 2022; collaboration revenue $1.8M (up from $0.8M).
Bolt Biotherapeutics reports positive BDC-1001 Phase 1 data; advances to Phase 2; cash $192.8M
BDC-1001 elicited objective responses including partial responses and stable disease across multiple HER2+ solid tumors as monotherapy and with nivolumab.
Bolt Biotherapeutics appoints Laura Berner to Board of Directors
Board expanded from 9 to 10; Laura Berner appointed as Class I director, term through 2025 annual meeting.
Bolt Biotherapeutics Q3 2022 operating loss $22.3M; cash $209.6M funds through 2025
Cash $209.6M as of Sep 30, 2022; expected to fund operations and milestones through 2025.
Bolt Biotherapeutics Q2 loss $23.1M; cash $223.6M extends runway to 2025
Collaboration revenue $1.4M vs $0 in Q2 2021; R&D spend $18.9M, G&A $5.5M.
Shareholders elect three Class I directors and ratify PwC as auditor for FY2022
Frank D. Lee (23,819,385 votes for), Brian O'Callaghan (22,559,100), Mahendra G. Shah (19,746,587) elected to Board.
Bolt Biotherapeutics Q1 2022: Cash $246.8M; BDC-1001 data on track for H2 2022
Cash, cash equivalents and marketable securities $246.8M at March 31, 2022; expected to fund operations into 2024.
Bolt Biotherapeutics reports 2021 results; cash $271.6M, BDC-1001 on track for RP2D in 2022
Cash, cash equivalents, and marketable securities $271.6M at Dec 31, 2021 vs $22.8M at end 2020; runway into 2024.
Bolt Biotherapeutics CSO David Dornan resigns, stays as consultant for 6 months
David Dornan, Ph.D. resigned as Chief Scientific Officer effective March 11, 2022.
Amended supply agreement with EirGenix for bulk drug substance EG12014, a trastuzumab biosimilar used in BDC-1001 HER2 Boltbody ISAC.
Bolt Biotherapeutics appoints Nicole Onetto to board; Ashish Khanna resigns
Ashish Khanna resigned from Bolt board and its Audit and Compensation committees effective Dec 13, 2021; no disagreement.
Bolt Biotherapeutics reports interim Phase 1/2 BDC-1001 data: safe, 1 durable PR at 52 weeks, no CRS
BDC-1001 showed favorable safety in 57 patients; no dose-limiting toxicities up to 20 mg/kg Q3W and 12 mg/kg Q2W.
Bolt Biotherapeutics appoints two new directors and lead independent director
Director Peter Moldt resigned from Board and Compensation Committee; no disagreement.
Bolt Biotherapeutics Q3 2021: cash $290.5M; BDC-1001 interim data at ESMO I-O in Dec
Cash, cash equivalents and marketable securities $290.5M at Sep 30, 2021; plus $5M upfront from Innovent in Oct.
Bolt Biotherapeutics Q2 cash $310.9M; R&D spend doubles; Genmab collaboration on track
Cash, cash equivalents, and marketable securities of $310.9M as of June 30, 2021, expected to fund operations through end of 2023.
Effective September 3, 2024, the Board appointed Jakob Dupont, M.D., Ph.D., to serve as a Class II member of the Board.
On September 1, 2024, Frank D. Lee notified the Company of his resignation as a member of the Board and the committees thereof, effective as of September 3, 2024.
On August 28, 2024, James Healy, M.D., Ph.D., notified Bolt Biotherapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and the committees thereof, effective as of September 3, 2024.
On May 13, 2024, Edgar G. Engleman, M.D. notified the Company of his resignation as a member of the Company's Board of Directors (the “Board”) and from all committees of the Board on which he served, effective as of May 15, 2024.
Edith A. Perez, M.D. is stepping down as the Company’s Chief Medical Officer of the Company, effective as of May 15, 2024.
Randall C. Schatzman, Ph.D. is stepping down as the Company’s Chief Executive Officer and has resigned as a member of the Board, both effective as of May 15, 2024.
Randall C. Schatzman, Ph.D. is stepping down as the Company’s Chief Executive Officer and has resigned as a member of the Board, both effective as of May 15, 2024.
the Board then appointed Laura Berner to the Board as a Class I director of the Company, effective immediately
On March 1, 2022, David Dornan, Ph.D. notified Bolt Biotherapeutics, Inc. of his resignation as our Chief Scientific Officer, effective March 11, 2022.
On December 14, 2021, upon recommendation of the Nominating and Corporate Governance Committee, the Board appointed Nicole Onetto to the Board as a Class III director of the Company, effective immediately, to fill the vacancy on the Board.
On December 13, 2021, Ashish Khanna, a director of Bolt Biotherapeutics, Inc. (the “Company”) resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.
On November 15, 2021, Peter Moldt, a director of Bolt Biotherapeutics, Inc. (the “Company”) resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event earnings